Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akorn signed a five-year contract manufacturing and supply agreement with a major US pharmaceutical company.
Subscribe to our email newsletter
Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product that will be manufactured at the company’s Somerset, New Jersey facility. Akorn is the ANDA holder and also expects to launch this drug product under the Akorn label in mid-2008.
Arthur Przybyl, president and CEO of Akorn, said: “We continue to seek contract pharmaceutical manufacturing opportunities in ophthalmics, liquid injectables and lyophilized products in order to expand these businesses.”